Payment is a benefit and why it matters for pediatric trials
Alan Wertheimer has argued persuasively that research ethics committees should be willing to count payment as a benefit when evaluating studies' risk–benefit ratios. In this paper, I begin by first recapitulating his argument and adding my own, complementary one. I then do two further things. F...
| Autor principal: | |
|---|---|
| Tipo de documento: | Electrónico Artículo |
| Lenguaje: | Inglés |
| Verificar disponibilidad: | HBZ Gateway |
| Journals Online & Print: | Gargar...
|
| Fernleihe: | Fernleihe für die Fachinformationsdienste |
| Publicado: |
Wiley-Blackwell
2022
|
| En: |
Bioethics
Año: 2022, Volumen: 36, Número: 7, Páginas: 757-764 |
| Clasificaciones IxTheo: | NCH Ética de la medicina NCJ Ética de la ciencia |
| Otras palabras clave: | B
benefit analyses / risk
B research ethics B children and families |
| Acceso en línea: |
Volltext (lizenzpflichtig) Volltext (lizenzpflichtig) |
| Sumario: | Alan Wertheimer has argued persuasively that research ethics committees should be willing to count payment as a benefit when evaluating studies' risk–benefit ratios. In this paper, I begin by first recapitulating his argument and adding my own, complementary one. I then do two further things. First, I explain why the practical implications of these arguments for studies enrolling competent adults are less than fully clear. Second, I explain why the practical implication for trials enrolling children are clear and significant. I argue that we should be comfortable paying children to compensate them for undergoing research risks. I propose we do so by putting money into accounts that the child gains access to upon attaining majority. |
|---|---|
| ISSN: | 1467-8519 |
| Obras secundarias: | Enthalten in: Bioethics
|
| Persistent identifiers: | DOI: 10.1111/bioe.13011 |